CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6068 result(s)

brolucizumab (Beovu)

Last Updated: July 3, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: brolucizumab
Indications: Macular degeneration, age-related

  • Brand Name: Beovu
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0632-000
  • Project Status: Complete
  • Submission Type: New

esketamine hydrochloride (Spravato)

Last Updated: July 2, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: esketamine hydrochloride
Indications: Major depressive disorder (MDD), adults

  • Brand Name: Spravato
  • Manufacturer: Janssen Inc.
  • Project Number: SR0621-000
  • Project Status: Active
  • Submission Type: New

eculizumab (Soliris )

Last Updated: July 2, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: eculizumab
Indications: Myasthenia Gravis (gMG), adults

  • Brand Name: Soliris
  • Manufacturer: Alexion Pharma Canada Corp.
  • Project Number: SR0605-000
  • Project Status: Active
  • Submission Type: New

emicizumab (Hemlibra)

Last Updated: July 1, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: emicizumab
Indications: Bleeding prevention, hemophilia A

  • Brand Name: Hemlibra
  • Manufacturer: Hoffmann-La Roche Ltd.
  • Project Number: ST0651-000
  • Project Status: Received
  • Submission Type: New

Halobetasol propionate and tazarotene (Duobrii)

Last Updated: June 30, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: Halobetasol propionate and tazarotene
Indications: Psoriasis, moderate to severe plaque

  • Brand Name: Duobrii
  • Manufacturer: Bausch Health, Canada Inc.
  • Project Number: SR0638-000
  • Project Status: Active
  • Submission Type: New

caplacizumab (Cablivi)

Last Updated: June 30, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: caplacizumab
Indications: Acquired thrombotic thrombocytopenic purpura (aTTP)

  • Brand Name: Cablivi
  • Manufacturer: Sanofi-Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0633-000
  • Project Status: Active
  • Submission Type: New